Evidence for the role of gonadotropin hormones in the development of Alzheimer disease.
Differences in the prevalence and age of onset of Alzheimer disease (AD) in men and women, and observations that hormone replacement therapy (HRT) may prevent the development of AD, caused many to hypothesize that estrogen deficiency contributes to AD. However, recent trials using estrogen failed to show any benefit in preventing or alleviating the disease. To address this and other inconsistencies in the estrogen hypothesis, we suspect that another hormone of the hypothalamic-pituitary-gonadal axis, luteinizing hormone (LH), as a major factor in AD pathogenesis. Individuals with AD have elevated levels of LH when compared with controls, and both LH and its receptor are present in increased quantities in brain regions susceptible to degeneration in AD. LH is also known to be mitogenic, and could therefore initiate the cell cycle abnormalities known to be present in AD-affected neurons. In cell culture, LH increases amyloidogenic processing of amyloid-beta protein precursor, and in animal models of AD, pharmacologic suppression of LH and FSH reduces plaque formation. Given the evidence supporting a pathogenic role for LH in AD, a trial of leuprolide acetate, which suppresses LH release, has been initiated in patients.
Casadesus
G
G
Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Atwood
C S
CS
Zhu
X
X
Hartzler
A W
AW
Webber
K M
KM
Perry
G
G
Bowen
R L
RL
Smith
M A
MA
D000375:Aging / Q000502:physiology; D000544:Alzheimer Disease / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control; D005260:Female; D006062:Gonadotropins / Q000502:physiology*; D006801:Humans; D007986:Luteinizing Hormone / Q000627:therapeutic use; D008297:Male
D006062:Gonadotropins; D007986:Luteinizing Hormone
Eur J Heart Fail. 2012 Aug;14 (8):931-8
22613584
EuroIntervention. 2014 Sep;10 Suppl U:U115-9
25256324
EuroIntervention. 2016 Feb;11(10 ):1126-31
26342591
J Am Coll Cardiol. 2014 Mar 11;63(9):914-9
24076529
J Am Coll Cardiol. 2014 Oct 28;64(17):1814-9
25443704
EuroIntervention. 2014 Sep;10 Suppl U:U120-8
25256325
JACC Cardiovasc Interv. 2015 Jul;8(8):1095-1104
26117461
Ann Thorac Surg. 2009 May;87(5):1431-7; discussion 1437-9
19379881
J Am Coll Cardiol. 2005 Feb 1;45(3):381-7
15680716
Kardiol Pol. 2013;71(12 ):1287-92
24399585
N Engl J Med. 1996 Nov 7;335(19):1417-23
8875918
JACC Cardiovasc Interv. 2014 Nov;7(11):1326-8
25326746
EuroIntervention. 2015 Sep;11 Suppl W:W58-9
26384192
Ann Thorac Surg. 2015 Jul;100(1):e21-3
26140803
Eur Heart J. 2007 Jun;28(11):1358-65
17350971
J Am Coll Cardiol. 2015 Jun 2;65(21):2352-3
26022826
JACC Cardiovasc Interv. 2014 Jun;7(6):696-7
24835326
J Am Coll Cardiol. 2015 May 26;65(20):2184-94
25787196
Circulation. 2013 Aug 6;128(6):e74-6
23918190
J Thorac Cardiovasc Surg. 2014 Jan;147(1):95-9
24100100
Circulation. 2009 Jul 28;120(4):326-33
19597051
Heart Lung Circ. 2014 Nov;23(11):1020-8
25038030
Catheter Cardiovasc Interv. 2014 Jun 1;83(7):E287-91
24532349
Lancet. 2009 Apr 18;373(9672):1382-94
19356795
EuroIntervention. 2015 Sep;11 Suppl W:W45-6
26384188
Lancet. 2006 Sep 16;368(9540):1005-11
16980116
Ann Thorac Surg. 2004 Sep;78(3):794-9; discussion 794-9
15336993
Eur J Cardiothorac Surg. 2011 Oct;40(4):840-7
21459603